New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
09:07 EDTPCYCPharmacyclics has several positive catalysts, says RBC Capital
RBC Capital believes that Pharmacyclics provided conservative guidance, while the company is poised to report higher than expected 2014 revenue and expert feedback on its Imbruvica drug is positive. The firm cut its price target on the shares to $110 from $150 but keeps an Outperform rating on the stock.
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PCYC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use